|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1996-2-14
|
|
pubmed:abstractText |
Within the Lovastatin Restenosis Trial, restenosis has been clearly shown to increase resource utilization and costs. While it is not possible to generalize these results to other patient populations, it is clear that successful efforts to decrease restenosis will certainly improve efficacy while decreasing follow-up costs and increasing the cost-effectiveness of intervention in the coronaries.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0002-9149
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
77
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
196-9
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:8546093-Adult,
pubmed-meshheading:8546093-Aged,
pubmed-meshheading:8546093-Angioplasty, Balloon, Coronary,
pubmed-meshheading:8546093-Anticholesteremic Agents,
pubmed-meshheading:8546093-Coronary Disease,
pubmed-meshheading:8546093-Cost-Benefit Analysis,
pubmed-meshheading:8546093-Double-Blind Method,
pubmed-meshheading:8546093-Female,
pubmed-meshheading:8546093-Humans,
pubmed-meshheading:8546093-Lovastatin,
pubmed-meshheading:8546093-Male,
pubmed-meshheading:8546093-Middle Aged,
pubmed-meshheading:8546093-Prospective Studies,
pubmed-meshheading:8546093-Recurrence,
pubmed-meshheading:8546093-Treatment Outcome
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Costs of coronary restenosis (Lovastatin Restenosis Trial).
|
|
pubmed:affiliation |
Department of Medicine, Emory University School Medicine, Atlanta, Georgia, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
